Biopharma Makes 'Solid Clinical Progress' in Q2/21
Source: Streetwise Reports��(8/4/21)
The highlights of Oryzon Genomics' Q2/21 clinical advancements were recapped in a Roth Capital Partners report. More >

Novavax Shares Get a Boost as EC Orders up to 200 Million Doses of Its COVID-19 Vaccine
Source: Streetwise Reports��(8/4/21)
Novavax Inc. shares traded nearly 19% higher after the company reported the finalization of an advance purchase agreement with the European Commission to provide up to 200 million doses of its COVID-19 Vaccine. More >

Translate Bio Shares Rise 29% on Sanofi's $3.2 Billion Buyout Bid
Source: Streetwise Reports��(8/3/21)
Shares of Translate Bio Inc. soared to a new 52-week high after the company reported it agreed to be acquired by its collaborative partner Sanofi SA for $38 per share in cash in a deal valued at $3.2 billion. More >

Gene Editing May Terminate Virus Transmission, Combat Heart and Brain Disease With a Single Shot
Source: McAlinden Research for Streetwise Reports��(8/2/21)
McAlinden Research Partners explores the acceleration of gene-editing technology and notes the market is poised to expand as the World Health Organization (WHO) creates new standards for companies to follow. More >

Annovis Shares Rise on Positive Phase 2 Alzheimer's and Parkinson's Disease Trial Results
Source: Streetwise Reports��(8/2/21)
Shares of Annovis Bio Inc. traded 20% higher after the company reported positive interim data from its Phase 2 clinical studies of ANVS401 (Posiphen) for treatment of Alzheimer's and Parkinson's diseases. More >

Sorrento Therapeutics Proceeds with COVID-19 Drug Treatment Trial
Source: Streetwise Reports��(7/28/21)
The latest developments concerning Sorrento Therapeutics, its product portfolio and partners are summarized in a Dawson James Securities report. More >

Biopharma Creates New Business Unit Ahead of Commercial Product Launch
Source: Streetwise Reports��(7/28/21)
The purpose of HTG Molecular Diagnostics' new therapeutics division and early interest in the biopharma's commercial-ready Transcriptome Panel are covered in an H.C. Wainwright & Co. report. More >

Rritual Superfoods at Full-Throttle, Adding CVS, Amazon Along the US Distribution Superhighway
Source: Knox Henderson for Streetwise Reports��(7/28/21)
Knox Henderson takes a close look at Rritual Superfoods and its plans to ramp up mass distribution. More >

Tilray Shares Fly High on Strong Q4 and FY Revenue Growth
Source: Streetwise Reports��(7/28/21)
Shares of Tilray Inc. traded 25% higher after the company reported FY/21 financial results that included a 27% YoY increase in net revenues to $513.1 million driven by a 55% growth in cannabis revenue following its Aphria acquisition. More >

Cannabis Market Delivering for Consumers and Investors
Source: Streetwise Reports��(7/21/21)
As legalization takes hold across the U.S., opportunities for the next generation of cannabis companies expand. Adrian Morante of K2 & Associates finds “trustworthy, capable and reputable” companies with value. More >

Coverage Initiated on Company with a 'Genuine Physiological Heart Replacement Therapy'
Source: Streetwise Reports��(7/21/21)
The investment thesis for the device company Carmat, whose therapy "allows patients to live with almost normal quality of life," is presented in an H.C. Wainwright & Co. report. More >

Biopharma Partners with NIH to Advance Women's Hormone-Free Contraceptive
Source: Streetwise Reports��(7/21/21)
A Roth Capital Partners report calls this a "very cost-effective and strategic move" for Daré Bioscience. More >

Rapidly Growing Virtual Healthcare Firm Adds Three New US Group Medical Practice Clients
Source: Streetwise Reports��(7/21/21)
Reliq Health Technologies advised it entered into agreements with three physician practices in Texas for its iUGO Care platform. More >

HCA Healthcare Shares Gain 15% on Strong Q2 Performance and Raised FY Outlook
Source: Streetwise Reports��(7/20/21)
HCA Healthcare shares established a new 52-week high after the company reported a greater than 30% increase in YoY revenue in Q2/21. More >

Small Bio-tech Gets $17.7 Million Backing from U.S. Department of Defense to Treat SARS-CoV-2 Delta Variant
Source: Streetwise Reports��(7/20/21)
Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets. More >

Cytokinetics Shares Rise 41% on Positive Phase 2 Redwood-HCM Trial Data
Source: Streetwise Reports��(7/19/21)
Cytokinetics Inc. shares reached a new 52-week high after the company reported positive topline results from its Phase 2 CK-274 hypertrophic cardiomyopathy clinical trial. More >

Zynex Shares Rise as Firm Notches Significant Q2 Order Growth and Raises EBITDA Outlook
Source: Streetwise Reports��(7/16/21)
Zynex Inc. shares traded 10% higher after the electrotherapy medical device maker reported a 247% YoY growth in orders during Q2/21 and raised the range for its EBITDA estimates in the quarter by $1.2 million. More >

Merger of Two Biopharmas 'Brings a New Dawn'
Source: Streetwise Reports��(7/14/21)
The implications of the Aerpio Pharmaceuticals–Aadi Bioscience transaction and the outlook and future for the combined company's lead drug candidate are discussed in an H.C. Wainwright & Co. report. More >

FDA, EMA Approve Drug Firm's Phase 3 Liver Cancer Trial Design
Source: Streetwise Reports��(7/14/21)
The recent news regarding Can-Fite BioPharma is reviewed in a Dawson James Securities report. More >

US Cannabis Sales Hold Strong as Industry Lays Out New Lobbying Efforts to Expedite Federal Reform
Source: McAlinden Research for Streetwise Reports��(7/14/21)
McAlinden Research Partners expects activity and revenues in the cannabis space to continue ramping up as the US crosses the point at which legalization is not a question of "if" but "when." More >

Alphatec Shares Rise After Firm Announces Strong Organic Revenue Growth in Q2
Source: Streetwise Reports��(7/12/21)
Alphatec Holdings Inc. shares traded 12% higher after the company reported preliminary Q2/21 financial results that included a larger than 90% increase in YoY organic revenue. More >

Pharma Company Working to Unlock Psychedelic Drug's Potential for Stroke Recovery
Source: Streetwise Reports��(7/9/21)
Algernon Pharmaceuticals CEO Christopher J. Moreau and Dr. David Nutt, the company's research stroke consultant, discuss Algernon's upcoming Phase 1 study of DMT for stroke. More >

Biopharma Files New Drug Application for Lead Clinical Product
Source: Streetwise Reports��(7/7/21)
A review of Daré Bioscience's lead clinical product for bacterial vaginosis and a potential timeline to commercialization are provided in a Roth Capital Partners report. More >

Biotech 'Strikes Again,' Identifies Gene Mutation that Protects Against Obesity
Source: Streetwise Reports��(7/7/21)
The encouraging work Regeneron Pharmaceuticals completed thus far, and the next challenge in this program, are laid out in an H.C. Wainwright & Co. report. More >

Biohaven Posts Revenue of $93 Million in Q2 for Its Migraine Medicine
Source: Streetwise Reports��(7/7/21)
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded 12% higher to a new 52-week high after the company reported preliminary Q2/21 net product revenue of $93 million for NURTEC ODT, which it claims is the first and only FDA approved medicine for both acute and preventive migraine treatment. More >